(Q37755975)

22 August 2017

1 reference

title

Molecular and clinical prodrome of Parkinson disease: implications for treatment (English)

1 reference

22 August 2017

1 reference

2

Eduardo Tolosa

1 reference

22 August 2017

1

Anthony H V Schapira

1 reference

PubMed ID

20479780

22 August 2017

language of work or name

English

0 references

publication date

18 May 2010

1 reference

22 August 2017

Nature Reviews Neurology

1 reference

22 August 2017

6

1 reference

22 August 2017

6

1 reference

22 August 2017

309-317

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2010.52

22 August 2017

0 references

cites work

What causes cell death in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Excessive daytime sleepiness in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Science, medicine, and the future: Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Why have we failed to achieve neuroprotection in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Etiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Genomic and proteomic biomarkers for Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Perspectives on recent advances in the understanding and treatment of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Diagnosis and the premotor phase of Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Non-motor symptoms of Parkinson's disease: diagnosis and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Neurobiology and treatment of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Autophagy and neurodegeneration: when the cleaning crew goes on strike

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

The roles of intracellular protein-degradation pathways in neurodegeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Mechanisms of chaperone-mediated autophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Peptide sequences that target cytosolic proteins for lysosomal proteolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

alpha-Synuclein locus triplication causes Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Genetic variability in the SNCA gene influences α-synuclein levels in the blood and brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Is Parkinson's disease a prion disorder?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Mitochondrial complex I deficiency in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Mitochondria in the aetiology and pathogenesis of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Parkin enhances mitochondrial biogenesis in proliferating cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

The PINK1/Parkin pathway regulates mitochondrial morphology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Parkin is recruited selectively to impaired mitochondria and promotes their autophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

PINK1 is selectively stabilized on impaired mitochondria to activate Parkin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Analysis of mutant DNA polymerase gamma in patients with mitochondrial DNA depletion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

PINK1 controls mitochondrial localization of Parkin through direct phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Genome-wide association study reveals genetic risk underlying Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

The cell biology of lysosomal storage disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Olfaction and Parkinson's syndromes: its role in differential diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Association of olfactory dysfunction with risk for future Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Idiopathic hyposmia as a preclinical sign of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Diagnostic performance of clinical motor and non-motor tests of Parkinson disease: a matched case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Staging of brain pathology related to sporadic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

31 March 2020

The Parkinson chimera

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Incidental Lewy body disease and preclinical Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Novel pharmacological targets for the treatment of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Evidence to support early levodopa therapy in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Mechanisms compensating for dopamine loss in early Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Neuroprotection trials in Parkinson's disease: systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

When and how should treatment be started in Parkinson disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Treatment options in the modern management of Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

Levodopa in the treatment of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2010.52

31 March 2020

Identifiers

DOI

10.1038/NRNEUROL.2010.52

1 reference

22 August 2017

1 reference

PubMed ID

20479780